Skip to main navigation Skip to search Skip to main content

Giant prolactinomas in men: efficacy of cabergoline treatment

  • Salvatore Maria Corsello
  • , G Ubertini
  • , M Altomare
  • , Rm Lovicu
  • , Mg Migneco
  • , Carlo Antonio Rota
  • , Cesare Colosimo

Research output: Contribution to journalArticle

Abstract

The term 'giant prolactinoma' can be used for tumours larger than 4 cm in diameter and/or with massive extrasellar extension. Cabergoline (CAB), a long-lasting dopamine agonist (DA), safe and well tolerated, is effective in normalizing PRL levels and inducing tumour shrinkage in micro- and macroprolactinomas. The purpose of this prospective study was to evaluate the efficacy and safety of CAB also for giant prolactinomas.
Original languageEnglish
Pages (from-to)662-670
Number of pages9
JournalClinical Endocrinology
Volume58
Publication statusPublished - 2003

Keywords

  • Adrenal Glands
  • Adult
  • Aged
  • Antineoplastic Agents
  • Erectile Dysfunction
  • Ergolines
  • Humans
  • Hypothyroidism
  • Libido
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Pituitary Gland
  • Pituitary Neoplasms
  • Prolactin
  • Prolactinoma
  • Vision Disorders

Fingerprint

Dive into the research topics of 'Giant prolactinomas in men: efficacy of cabergoline treatment'. Together they form a unique fingerprint.

Cite this